Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hovelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L
Clinical Efficacy (Phase 2): In trials, high doses (9 mg) led to a mean body weight reduction of roughly 20.1% (-21.3 kg) over 48 weeks
In the sponsor-submitted ITC, there was || |||||||| ||| | |||||||||| || |||| || |||| ||||||| ||||||||||| ||| ||||||||||| ||| ||| |||| ||||||| || |||||||||| ||| ||||||||||| ||| |||||||| ||| || ||||| ||||| |||||| Conclusions Data from 4 placebo-controlled DB RCTs (the STEP 1, STEP 2, STEP 3, and STEP 4 trials) and 1 open-label RCT comparison to liraglutide (the STEP 8 trial) suggest that treatment with semaglutide injection 2.4 mg for 68 weeks produces a statistically significant weight loss compared to liraglutide and to placebo in patients with overweight or obesity, including patients with comorbid type 2 diabetes
In total, 15,107 (or 15.9 percent) had been exposed to GLP-1 agonists, meaning they received their first prescription before undergoing breast imaging
